Sunshine Biopharma (SBFM) Stock: Buy, Sell, or Hold?
SBFM - Sunshine Biopharma Inc.
$0.67
-0.02 (-3.07%)
▼
5d:
-20.9%
30d:
-43.03%
90d:
-69.43%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When SBFM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SBFM is down 20.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SBFM is down 20.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SBFM is currently trading at $0.67, which is considered oversold relative to its 30-day fair value range of $0.82 to $1.16. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.7) compared to its historical average (13.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SBFM is in a downtrend. The price is currently testing key support at $0.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $56.00 (+8302.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SBFM is in a downtrend. The price is currently testing key support at $0.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $56.00 (+8302.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.82 -
$1.16
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 8302.1% below Wall St target ($56.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.82 -
$1.16
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.67
Resistance Level
$0.97
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.67
Wall Street Target
$56.00
(+8302.1%)
Revenue Growth (YoY)
-1.6%
Profit Margin
-16.5%
PE vs Historical
-1.7 vs 13.1
CHEAP
Share & Embed Analysis
Last updated: October 04, 2026 4:37 AM ET
Data refreshes hourly during market hours. Next update: 5:37 AM
Data refreshes hourly during market hours. Next update: 5:37 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SBFM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
